TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient or volunteer is 18 years of age or older~* Patients must have indication for diagnosis and/or therapy of diseases of the oropharynx, hypopharynx, and/or larynx.~Exclusion Criteria:~* unexplained fever and/or untreated~* active infection~* pregnancy~* anatomic parameters which preclude transoral surgery, such as:~  1. trismus~ 2. limited range of neck motion~ 3. poor dentition~ 4. redundant hypopharyngeal or supraglottic tissue which would prevent adequate visualization of the tumor~* participation in a research protocol which precludes participation in other protocols

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transoral Robotic Surgery (Type: OTHER): Pilot study; single arm - use of da Vinci Surgical Robot Platform to access neoplastic disease of the upper aerodigestive tract.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Flourish HEC Vaginal Care System on Birth-Related Pelvic Floor Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women over the age of 18~2. Vaginal delivery within the past year~3. Attending a pelvic physical therapy clinic treatment of birth-related pelvic floor disorder with one or more of the following symptoms: vulvovaginal pain, pelvic/bladder pain, urinary or fecal incontinence, or dyspareunia.~4. Needing approximately three months of treatment sessions~Exclusion Criteria:~1. Known allergies or sensitivities to any ingredients of the Flourish HEC Vaginal Care System~2. Immunosuppressed or otherwise immunocompromised~3. Vaginal infection at the start of the study other than bacterial vaginosis or yeast infection (these may be treated prior to starting the protocol)~4. Current use of any antibiotics~5. Surgery within the past 3 months~6. Pregnant or trying to conceive during the trial~7. Recent (within past 6 months) usage of any Good Clean Love products~8. Psychiatric/mental disorders triggered by questions related to vulvar or vaginal health, by pelvic exams

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine Care (Type: ACTIVE_COMPARATOR): Women will undergo routine pelvic physical therapy for birth-related pelvic floor disorders as determined by their physical therapist who is also the Principal Investigator.
- Flourish HEC (Type: EXPERIMENTAL): In addition to routine physical therapy, women will use a 3-component vaginal hygiene system, Flourish HEC (HEC = hydroxyethylcellulose to differentiate this system from a prior Flourish system based in aloe) plus a personal lubricant called BioNude.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 0-18 with juvenile myelomonocytic leukemia (JMML) who have relapsed or have residual disease after allogeneic HCT. Residual disease is defined as failure to eradicate original disease without prior documentation of remission. Relapse is defined as reappearance of i) leukocytosis with absolute monocytosis \>1 x 10\^8/L, ii) presence of immature myeloid cells in the peripheral circulation in two consecutive bone marrow specimens taken at least one month apart, or iii) presence of clonal cytogenetic abnormality. The diagnosis of relapse will be supported by the return of an abnormal cytogenetic marker (if present at diagnosis) or the presence of host cells by RFLP or other method.~* Patients should be at least 6 months from first hematopoietic cell transplant (HCT) if clinically stable. (If JMML is rapidly progressive, second HCT may be performed earlier).~  * Adequate major organ function including:~    * Cardiac: ejection fraction ≥45%~   * Pulmonary: FEV \>50%, DLCO \>50%~ * Renal: creatinine clearance ≥40 mL/min~    * Hepatic: no clinical evidence of hepatic failure (e.g. coagulopathy, ascites)~ * Karnofsky performance status ≥70% or Lansky score ≥50%~* Written informed consent.~Exclusion Criteria:~* Active uncontrolled infection within one week of HCT.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cytarabine + Mitoxantrone (Type: EXPERIMENTAL): This is a phase I-II study designed to evaluate the efficacy of the administration of high dose cytosine arabinoside and mitoxantrone followed by HCT in patients with JMML who have residual disease or have relapsed after initial HCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Participants must had a known diagnosis of acute lymphoblastic leukemia (ALL) of T cell origin, including T-LBL and T-ALL with extramedullary involvement at relapse confirmed by biopsy.~* Participants must be previously treated for T-ALL or T-LBL and have relapsed or are refractory to most recent treatment. Participants in first relapse were be eligible regardless of the first remission duration.~* Participants must had been previously exposed to nelarabine in countries where this drug is available (unless due to a contraindication to its use or administrative issue).~* No more than 3 prior salvage therapies.~Exclusion criteria:~* Prior treatment with immunotherapy/investigational agents within 3 weeks, chemotherapy within 2 weeks of study treatment. Must have recovered from acute toxicity before first study treatment administration.~* Prior stem cell transplant within 4 months and/or evidence of active systemic Graft versus Host Disease and/or immunosuppressive therapy for Graft versus Host Disease within 1 week before the first study treatment administration.~* Clinical evidence of active central nervous system (CNS) leukemia.~* T-ALL with testicular involvement alone.~The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Isatuximab (Type: EXPERIMENTAL): Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage I, II, or III multiple myeloma with protein criteria present Quantifiable M-components of IgG, IgA, IgD, IgE AND/OR Urinary kappa or lambda light chain excretion No IgM peaks Quantifiable monoclonal proteins Received at least 1, but no more than 4 prior treatment regimens, including the following: Chemotherapy Bone marrow transplantation Biologic therapy Radiotherapy Interferon therapy or steroid pulsing given as maintenance therapy after transplantation or chemotherapy is not considered a separate treatment regimen Progressive disease~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Zubrod 0-2 (3-4 allowed if due solely to bone pain) Life expectancy: At least 3 months Hematopoietic: Absolute granulocyte count at least 1,000/mm3 Platelet count at least 50,000/mm3 (at least 50% plasma cells in bone marrow) Hepatic: Bilirubin no greater than 2.5 times upper limit of normal (ULN) SGOT or SGPT no greater than 2.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use 2 methods of effective contraception for 4 weeks before, during, and for 4 weeks after study No other prior or concurrent malignancies within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other adequately treated stage I or II cancer in complete remission No grade 2 or greater preexisting peripheral neuropathy~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics Prior thalidomide allowed if received less than 3 months of therapy Recovered from prior biologic therapy Chemotherapy: See Disease Characteristics At least 3 weeks since prior chemotherapy and recovered No other concurrent chemotherapy Endocrine therapy: See Disease Characteristics No concurrent hormonal therapy Radiotherapy: See Disease Characteristics At least 3 weeks since prior extensive or limited radiotherapy and recovered No concurrent radiotherapy Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- chemo with thalidomide (Type: EXPERIMENTAL): chemo with thalidomide
- chemo without thalidomide (Type: ACTIVE_COMPARATOR): chemo without thalidomide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Respiratory Drive on Obstructive Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe OSA Apnea Hypopnea Index \> 20/hr.~* Minimum oxygen saturation by pulse oximetry (SpO2) during events \>70% throughout sleep during the clinical sleep study~Exclusion Criteria:~* Neuromuscular disease.~* Obesity-hypoventilation syndrome.~* Chronic obstructive pulmonary disease.~* Pregnancy.~* Significant comorbidities:~  1. Dialysis-dependant renal failure~ 2. Severe asthma~ 3. Congestive~ 4. Heart failure~ 5. Previous stroke~* Recent (within 3 months) myocardial infarction or Active coronary ischemia event.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dead space (Type: ACTIVE_COMPARATOR): Participant will sleep connected to a mask with added dead space half of the night
- room air (Type: SHAM_COMPARATOR): Participant will sleep connected to a mask open to rrom air, half of the night

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of COPD~* Aged between 35 and 90 years~* Able to fluently read and speak English~* Willing and able to sign informed consent~* Be able to comply with the procedures outlined for the study~Exclusion Criteria:~* Cardiac disease (including arrhythmias)~* A medicinal requirement for rate limiting calcium antagonists or beta blockers~* Cerebrovascular disease~* Peripheral vascular disease~* Requirement for supplemental oxygen therapy~* CO2 (carbon dioxide) retention~* Malignancy~* Orthopaedic or neurological conditions effecting the ability to exercise~* Clinically apparent heart failure~* Renal, hepatic or inflammatory disease~* Instability of COPD~* Any other reason leading to the inability to complete the requirements of the study.~Additionally: If participants have a resting HR above 120beats.min-1, systolic blood pressure above 180mm Hg or diastolic blood pressure above 100mm Hg prior to the 6 minute walk test they will not be able to commence the test.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Inspiratory Warm Up (Type: EXPERIMENTAL): (IWU). Two sets of 15 breaths
- Expiratory Warm Up (Type: EXPERIMENTAL): (EWU). Two sets of 15 breaths
- Combination Warm Up (Type: EXPERIMENTAL): (RWU). One set of 15 breaths inspiratory and one set of 15 breaths expiratory
- Control Trial (Type: OTHER): No warm up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with a suspected submucosal tumor in the upper GI tract that are available for both EUS-guided FNA and Endodrill biopsy~Exclusion Criteria:~* Mental illness~* Extreme co-morbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- EUS-FNA (Type: ACTIVE_COMPARATOR): All patients with a confirmed suspicion of a submucosal tumor in the upper GI tract will be included in this study. A senior endoscopist will perform multiple passes of EUS-FNA until she/he has collected enough material for the pathologist to establish a possible diagnosis.
- EUS-Endodrill biopsy (Type: ACTIVE_COMPARATOR): All patients who are included in the study will also be examined by a senior endoscopist performing multiple EUS guided passes with the Endodrill biopsy. The harvested tissue from the tumor will be examined by a pathologist in order to establish a diagnosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does Static Ultrasound-Preview Reduce the Incidence of Difficult Lumbar Puncture?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18~* Clinical need for lumbar puncture~* Unable to visualize spine in position for the lumbar puncture~Exclusion Criteria:~* Able to visualize the spinous processes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- No Ultrasound (Type: NO_INTERVENTION): Standard LP without ultrasound use
- Ultrasound Use (Type: EXPERIMENTAL): Ultrasound used to assess spine and best location for lumbar puncture.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD20 positive diffuse large B-cell lymphoma with bulky stage II or stage III or stage IV~* Bidimensionally measurable disease~* Performance status Zubrod 0-2~* Less than 20,000/mcL circulating lymphoid cells on WBC differential count~* No clinical evidence of CNS involvement, no prior diagnosis of indolent lymphoma, no histologic transformation~* Ejection fraction more than or equal to 45% by MUGA or no significant abnormality by echocardiogram~* Fertile patients with effective contraception method~* No other malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer, stage I or II cancer in complete remission, or carcinoma in situ of cervix~* No HIV positive, no prior solid organ transplantation~* No prior antibody therapy, chemotherapy, radiotherapy for lymphoma~Exclusion Criteria:~* Serum creatinine ot bilirubin more than 2.5 X ULN unless due to lymphoma~* Active uncontrolled infection~* Concurrent severe and/or uncontrolled medical disease which could compromise participation in the study~* Patients with more than 25% infiltrated bone marrow~* Patients with platelet counts less than 100,000/mcL or neutrophil counts less than 1,500/mcL

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 65 years or older undergoing total knee replacement surgery under spinal anesthesia.~2. ASA class 1-3~Exclusion Criteria:~1. Patients with coagulation abnormalities~2. End organ diseases of liver, lung or kidney~3. Severe aortic stenosis~4. High degree AV block~5. Heart failure~6. Patients on MAO inhibitors~7. History of seizures or epilepsy~8. Glaucoma

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Atropine group (Type: ACTIVE_COMPARATOR): Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
- Glycopyrrolate group (Type: ACTIVE_COMPARATOR): Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized patients with acute or chronic liver disease~* Type I HRS~* Aged greater than or equal to 18~* Non-pregnant~Exclusion Criteria:~* Allergy or hypersensitivity to PTX or intolerance to methylxanthines (e.g. caffeine, theophylline)~* Concurrent use of nephrotoxic drugs~* Age less than 18~* Pregnancy~* Uncontrolled bacterial infection~* Renal parenchymal disease (e.g. acute tubular necrosis, glomerular disease, interstitial nephritis and urinary obstruction)~* Shock~* TNF alpha antagonist use~* Subject is institutionalized or a prisoner~* Recent cerebral or retinal hemorrhage (contraindication to PTX)~* Severe or poorly controlled cardiovascular disease as determined by the principal investigator to hinder the ability to adhere to study protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Pentoxyfylline 400mg three times a day or 400mg twice a day for eGFR 10-50 and 400mg once a day for eGFR \<10 for 90 days in addition to standard AMO therapy
- Placebo (Type: PLACEBO_COMPARATOR): This is a standard placebo pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues